Ryan Haumschild, PharmD, MBA

An engineered Fc fusion protein is designed to circulate longer, resist oxidation, and hold levels within the true normal range between infusions, without depending on human plasma.

No trial has shown a significant FEV1 benefit, yet FEV1 may be the wrong yardstick for emphysema. CT densitometry and real-world comparisons support augmentation, while testing and liver coordination remain unmet needs.

Avoiding the twin traps of treating every SGLT2 inhibitor as identical, or as fundamentally different, Dr. Haumschild lays out an evidence-first framework for the years ahead.

A shared mechanism and similar composite results can still sit on top of meaningfully different mortality data, and P&T committees need to look past the headline number.

Fewer than two-thirds of patients prescribed augmentation begin infusions, and half of starters miss doses. Structured education lifts adherence sharply, while plasma supply and partial coverage expose the limits of current therapy.

Weekly dosing produces high early levels and a falling trough. Panelists explain how they balance exacerbations, travel, and infusion access, and why they discourage routine level monitoring once therapy begins.

A hundred-dollar pharmacy savings means little if it triggers a ten-thousand-dollar medical claim, and total cost of care, not the pharmacy PMPM, should drive the decision.

Growing GLP-1 kidney data doesn't make these two drug classes interchangeable, and neither does a formulary change that disrupts a patient already stable on therapy.

The 11 micromolar target was built on epidemiologic reasoning rather than a normal range. Pending trials of higher doses and longer-acting agents may show whether raising levels further improves outcomes.

Four plasma-derived products deliver the same purified protein and appear clinically interchangeable. Differences in formulation, administration, and coverage design shape which product a patient actually receives.

Screening alone is not the finish line. Dr. Haumschild explains why quality measures should track whether early CKD identification actually leads to kidney-protective therapy.

As generics reach the SGLT2 class, payers must separate genuine cost opportunity from clinical disruption, and resist reducing two very different CKD trials to a single number.

Cost data in AATD depend heavily on how patients are identified. Augmentation therapy adds a substantial burden, yet survival benefit and comorbidity management complicate any simple cost comparison for payers.

Clinicians cannot be expected to remember every rare disease. Default order sets, testing tied to pulmonary function results, and standardized genotyping can make AATD testing the easy choice rather than an added burden.

Fragmented care, siloed specialties, and outdated assumptions about glucose-only benefit are quietly keeping eligible patients off guideline-directed cardiorenal therapy.

SGLT2 inhibitors have outgrown their diabetes-only label, and formulary teams that still price them that way are missing the bigger cardiorenal picture entirely.

The same AAT level can mean very different protease burdens in two patients. Severe deficiency drives the highest risk, yet carriers and unusual alleles complicate any simple relationship between numbers and disease.

Decades of guidelines have recommended testing every patient with COPD, yet testing remains rare. The panel examines who gets missed, why clinicians believe they can spot AATD, and what health plans can do.

As the panel closes, cautious optimism prevails: new mechanisms, expanding access, and a deeper understanding of vitiligo's psychosocial toll all point toward meaningful, if gradual, progress for patients across every skin tone.

Will vitiligo treatment settle into a clear sequencing algorithm, or remain individualized? Dr. Lal and Jason weigh the absence of clinical guidelines against the reality that professional consensus typically lags well behind new therapies.

A serum level is a snapshot, while genotype is the blueprint. Relying on levels alone misses carriers and mislabels patients, and the resulting diagnostic gap carries real clinical and economic costs.

AATD is better understood as a genetic predisposition than a single disease. Genotype, codominant inheritance, and environmental exposure together shape who develops lung or liver disease and how severe it becomes.

With three oral JAK inhibitors advancing through Phase 3 trials, Dr. Rosmarin calls for consensus guidelines, while Dr. Desai details the practical advocacy, documentation, and coverage groundwork needed to get patients access.

As treatment options multiply, Jason and Dr. Lal weigh localized versus systemic delivery against body surface area, safety, and real-world absorption risk, questioning whether cost alone should keep topical therapy as the default choice.

Black box warnings drawn from a distinct, higher-risk population have colored perceptions of JAK inhibitor safety in vitiligo. Dr. Desai argues for contextualized risk communication, appropriate screening, and recognizing genuine comorbidity benefits.

Two years of ruxolitinib cream data show continued gains rather than a plateau, and Dr. Rosmarin argues that early initiation prevents a repigmentation gap patients never fully close. Jason explains why payers remain cautious regardless.

Repigmentation unfolds over months, not weeks, and Dr. Desai argues that managing expectations from the first visit matters as much as the medication itself. Dr. Lal adds that clinical-trial consistency rarely mirrors real-world adherence.

Without a head-to-head trial, comparing JAK inhibitors requires care. Dr. Rosmarin urges matching time points before drawing conclusions, while Jason explains how payers weigh incomplete data, member churn, and documentation when building coverage exceptions.

Age shapes more than pill-swallowing ability in pediatric vitiligo care. Dr. Lal explains how activity level, motivation, and comorbidities guide the choice between topical and oral therapy in younger patients, more than any single BSA threshold.

Trial enrollment ranges become policy boundaries in practice. Dr. Desai explains how broader BSA inclusion supports patients with widespread disease, while Jason describes how narrower criteria let payers manage the bulk of cases through topical therapy first.